Screening/Prevention
Hormone Therapy Increases Risk for Breast and Lung Cancers
(03/05/2008)
Hormone therapy appears to increase the risk of breast cancer as well as lung cancer among postmenopausal women. These results were recently published in the Journal of the American Medical Association.
Minimally Invasive Endoscopic Procedure Shows Promise for Detecting Lung Cancer
(02/08/2008)
Use of a minimally invasive technique called endoscopy to detect lung cancer may be more effective than more complicated and invasive standard procedures. These findings were recently published in the Journal of the American Medical Association.
Smoking Marijuana May Increase Risk of Lung Cancer
(02/06/2008)
Smoking marijuana may increase the risk of lung cancer. However, this risk was only identified in patients who smoked the most marijuana over a decade or more. These findings were reported in the European Respiratory Journal.
Women Married to Smokers Have Increased Risk of Lung Cancer
(01/08/2008)
According to the results of a combined analysis of previously published studies, nonsmoking women married to men who smoke are more likely to develop lung cancer than nonsmoking women married to nonsmoking men. These results were published in the International Journal of Epidemiology.
Meat Linked to Various Cancers
(12/13/2007)
According to an article recently published in the Public Library of Science Medicine journal, increased consumption of beef, pork, lamb, or processed meats such as bacon, sausage, or ham significantly increases the risk of developing several types of cancers.
More...
Stages I-IIIA
Avastin® plus Chemotherapy Shows Promise for Treatment of Non–Small Cell Lung Cancer
(04/30/2008)
The combination of Avastin® (bevacizumab), Gemzar® (gemcitabine), and Platinol® (cisplatin) prolonged progression-free survival when compared with chemotherapy alone among patients with non-small cell lung cancer. These results were recently reported by the pharmaceutical company Genentech.
Surgery Effective in Elderly Patients with Lung Cancer
(04/21/2008)
Surgery for the treatment of lung cancer in patients 80 years and older is a safe and effective treatment approach for those who are eligible. These results were recently presented at the American Association for Cancer Research 2008 Annual Meeting.
Differences in IMRT Radiation Doses May Complicate Study Results in Lung Cancer
(03/28/2008)
Differences between the prescribed dose of radiation in intensity modulated radiation therapy (IMRT) and the dose that’s actually delivered may make comparison studies in lung cancer difficult to interpret. These findings were reported in the Journal of the National Cancer Institute.
Activity of Four Genes in Stage I NSCLC Associated with Early Recurrence
(03/17/2008)
An activity known as methylation (addition of a molecule containing a carbon and 3 hydrogen atoms) of four genes in patients with Stage I non–small cell lung cancer (NSCLC) is associated with an early recurrence. These results were recently published in the New England Journal of Medicine.
American Society of Clinical Oncology Provides Guidelines for Adjuvant Therapy of Non–Small Cell Lung Cancer
(12/06/2007)
The American Society of Clinical Oncology and Cancer Care Ontario have published guidelines regarding the use of adjuvant (postsurgery) chemotherapy and adjuvant radiation therapy in patients with Stage I-IIIA non–small cell lung cancer that has been completely surgically removed. The guidelines were published in the Journal of Clinical Oncology.
More...
Stages IIIB-IV
Avastin® plus Chemotherapy Shows Promise for Treatment of Non–Small Cell Lung Cancer
(04/30/2008)
The combination of Avastin® (bevacizumab), Gemzar® (gemcitabine), and Platinol® (cisplatin) prolonged progression-free survival when compared with chemotherapy alone among patients with non-small cell lung cancer. These results were recently reported by the pharmaceutical company Genentech.
Disease Stabilization More Accurate than Responses in Predict Lung Cancer Outcomes
(01/28/2008)
According to an article recently published in the Journal of Clinical Oncology, the addition of disease stabilization to complete and partial responses at eight weeks appears to predict long-term outcomes more accurately than the standard measurement of responses for patients with advanced non–small cell lung cancer.
Vandetanib plus Taxotere® Shows Promise in Previously-treated Non–Small Cell Lung Cancer
(11/12/2007)
According to the results of a Phase II clinical trial published in the Journal of Clinical Oncology, treatment with vandetanib (an investigational targeted therapy) plus Taxotere® (docetaxel) may result in better progression-free survival than treatment with Taxotere alone among patients with previously-treated non–small cell lung cancer.
Advances in the Management of Advanced Non-Small Cell Lung Cancer
(03/25/2008)
Highlights from the 12th World Conference on Lung Cancer
Possible Progress in Vaccine Treatment of Non–Small Cell Lung Cancer
(11/05/2007)
According to the results of two studies presented at the 12th World Conference on Lung Cancer, experimental vaccines are showing some promise in the treatment of non–small cell lung cancer.
More...
Recurrent
Addition of Avastin® Superior to Chemotherapy Alone in Lung Cancer
(10/15/2007)
According to an article recently published in the Journal of Clinical Oncology, the addition of Avastin® (bevacizumab) to Tarceva® (erlotinib) or to chemotherapy improves survival compared with chemotherapy alone in the treatment of recurrent non–small cell lung cancer.
Iressa® and Taxotere® Provide Same Survival in Recurrent Non–Small Cell Lung Cancer
(09/06/2007)
According to results presented at the 2007 annual International Association for the Study of Lung Cancer (IASLC), Iressa® (gefitinib) may provide equal outcomes with an improved quality of life compared to Taxotere® (docetaxel) for the treatment of recurrent non–small cell lung cancer among patients who have received one prior treatment regimen.
Ixabepilone Has Anticancer Activity in Recurrent Non–Small Cell Lung Cancer
(08/09/2007)
According to an article recently published in the Journal of Clinical Oncology, the agent ixabepilone provides significant anticancer activity in the treatment of non–small cell lung cancer among patients who have experienced cancer progression following a platinum-based chemotherapy regimen.
Tarceva® May Be Option for Lung Cancer Patients Who Stop Responding to Iressa®
(07/11/2007)
According to an article recently published in the Journal of Clinical Oncology, the targeted agent Tarceva® (erlotinib) may provide anticancer responses for patients with non–small cell lung cancer (NSCLC) who stop responding to Iressa® (gefitinib).
Addition of Gliadel® Wafer to Surgery and Radiation Effective for Brain Metastasis
(06/22/2007)
According to an article in Clinical Cancer Research, the addition of Gliadel® Wafer (carmustine polymer wafer) to surgery plus external beam radiotherapy for the treatment of a single brain metastasis is a safe and effective regimen for patients.
More...